Ceapro Inc (CRPOF) 0.2072 $CRPOF
Ceapro to Present on Pressurized Gas Expanded Technology (PGX) at the 12th Annual BIO World Congress on Industrial Biotechnology
Marketwired - Thu Jul 09, 7:05AM CDT
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"
, a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that an abstract on its novel Pressurized Gas eXpanded (PGX) platform processing technology will be presented at the 12th Annual BIO World Congress on Industrial Biotechnology being held July 19-22, 2015, at the Montreal Convention Center, in Montreal, Canada.
CZO.VN: 0.250 (unch)
Ceapro Featured at the 12th International Congress on Engineering and Food (ICEF12)
Marketwired - Mon Jun 15, 7:02AM CDT
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company", a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced its featured participation in the 12th International Congress on Engineering and Food (ICEF12) being held June 14-18, 2015, at the Quebec City Convention Centre in Quebec City, Canada.
CZO.VN: 0.250 (unch)
Ceapro Announces Election of Directors at 2015 Shareholders' Meeting
Marketwired - Tue Jun 09, 7:03AM CDT
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company", a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that all proposed Directors, Mr. Gilles Gagnon, Dr. Ulrich Kosciessa, Dr. William W. Li, Mr. Don Oborowsky, Mr. Glenn R. Rourke and Mr. John Zupancic, were elected to serve for a one-year term at its annual meeting of shareholders held on June 3, 2015.
CZO.VN: 0.250 (unch)
Ceapro Inc. Reports First Quarter 2015 Financial and Operations Results
Marketwired - Mon Jun 01, 8:02AM CDT
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company", a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today its financial results for the three-months ended March 31, 2015 and provided an overview of recent operational highlights.
CZO.VN: 0.250 (unch)
Ceapro to Develop Enabling Pressurized Gas Expanded Technology (PGX) at Commercial and Demonstration Scale
Marketwired - Thu May 28, 6:05AM CDT
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company", a growth-stage biotechnology company focused on the development and commercialization of active ingredients for the healthcare and cosmetic industries, announced today it will embark on a scale-up of its proprietary PGX technology to commercial and demonstration levels.
CZO.VN: 0.250 (unch)
Ceapro Announces Appointment of New Chief Financial Officer
Marketwired - Tue May 05, 6:06AM CDT
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company", a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today it has appointed Stacy Prefontaine, CA, as Chief Financial Officer. Ms. Prefontaine replaces Branko Jankovic who is leaving his position effective immediately.
CZO.VN: 0.250 (unch)
Ceapro Appoints Seasoned Pharmaceutical Industry Executive, Ulrich Kosciessa, Ph.D., to its Board of Directors
Marketwired - Tue Apr 28, 7:03AM CDT
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company", a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today it has appointed international pharmaceutical industry expert, Ulrich Kosciessa, Ph.D., to its Board of Directors.
CZO.VN: 0.250 (unch)
Ceapro Reports Record Full-Year 2014 Financial Results
Marketwired - Wed Apr 22, 7:02AM CDT
Ceapro Inc. (TSX VENTURE: CZO) (Ceapro or the Company), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today its financial results for the twelve-months ended December 31, 2014 and provided an overview of recent operational highlights and expected business milestones for 2015.
CZO.VN: 0.250 (unch)
Ceapro Expands License Agreement With University of Alberta for PGX Technology
Marketwired - Wed Feb 11, 7:03AM CST
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company", a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced an expansion to its agreement with the University of Alberta for the development and commercialization of an innovative drying technology called Pressurized Gas eXpanded Technology (PGX) to include all fields of use, including emerging industrial opportunities. The original agreement was established in April 2014 for the development and commercialization of the PGX technology in select large markets like cosmeceuticals, functional food, nutraceuticals and pharmaceuticals.
CZO.VN: 0.250 (unch)
Ceapro Raises an Additional $310,000 Through a Non-Brokered Private Placement
Marketwired - Wed Feb 04, 4:01PM CST
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company", a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it has closed a $310,000 second tranche of its previously announced private placement of eight (
percent unsecured convertible debentures (the "Debentures" due December 31, 2016, with interest payable on June 30 and December 31 of each year.
CZO.VN: 0.250 (unch)
Ceapro to Present on Pressurized Gas Expanded Technology (PGX) at the 12th Annual BIO World Congress on Industrial Biotechnology
Marketwired - Thu Jul 09, 7:05AM CDT
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"
, a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that an abstract on its novel Pressurized Gas eXpanded (PGX) platform processing technology will be presented at the 12th Annual BIO World Congress on Industrial Biotechnology being held July 19-22, 2015, at the Montreal Convention Center, in Montreal, Canada. CZO.VN: 0.250 (unch)
Ceapro Featured at the 12th International Congress on Engineering and Food (ICEF12)
Marketwired - Mon Jun 15, 7:02AM CDT
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"
, a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced its featured participation in the 12th International Congress on Engineering and Food (ICEF12) being held June 14-18, 2015, at the Quebec City Convention Centre in Quebec City, Canada. CZO.VN: 0.250 (unch)
Ceapro Announces Election of Directors at 2015 Shareholders' Meeting
Marketwired - Tue Jun 09, 7:03AM CDT
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"
, a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that all proposed Directors, Mr. Gilles Gagnon, Dr. Ulrich Kosciessa, Dr. William W. Li, Mr. Don Oborowsky, Mr. Glenn R. Rourke and Mr. John Zupancic, were elected to serve for a one-year term at its annual meeting of shareholders held on June 3, 2015. CZO.VN: 0.250 (unch)
Ceapro Inc. Reports First Quarter 2015 Financial and Operations Results
Marketwired - Mon Jun 01, 8:02AM CDT
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"
, a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today its financial results for the three-months ended March 31, 2015 and provided an overview of recent operational highlights. CZO.VN: 0.250 (unch)
Ceapro to Develop Enabling Pressurized Gas Expanded Technology (PGX) at Commercial and Demonstration Scale
Marketwired - Thu May 28, 6:05AM CDT
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"
, a growth-stage biotechnology company focused on the development and commercialization of active ingredients for the healthcare and cosmetic industries, announced today it will embark on a scale-up of its proprietary PGX technology to commercial and demonstration levels. CZO.VN: 0.250 (unch)
Ceapro Announces Appointment of New Chief Financial Officer
Marketwired - Tue May 05, 6:06AM CDT
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"
, a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today it has appointed Stacy Prefontaine, CA, as Chief Financial Officer. Ms. Prefontaine replaces Branko Jankovic who is leaving his position effective immediately. CZO.VN: 0.250 (unch)
Ceapro Appoints Seasoned Pharmaceutical Industry Executive, Ulrich Kosciessa, Ph.D., to its Board of Directors
Marketwired - Tue Apr 28, 7:03AM CDT
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"
, a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today it has appointed international pharmaceutical industry expert, Ulrich Kosciessa, Ph.D., to its Board of Directors. CZO.VN: 0.250 (unch)
Ceapro Reports Record Full-Year 2014 Financial Results
Marketwired - Wed Apr 22, 7:02AM CDT
Ceapro Inc. (TSX VENTURE: CZO) (Ceapro or the Company), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today its financial results for the twelve-months ended December 31, 2014 and provided an overview of recent operational highlights and expected business milestones for 2015.
CZO.VN: 0.250 (unch)
Ceapro Expands License Agreement With University of Alberta for PGX Technology
Marketwired - Wed Feb 11, 7:03AM CST
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"
, a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced an expansion to its agreement with the University of Alberta for the development and commercialization of an innovative drying technology called Pressurized Gas eXpanded Technology (PGX) to include all fields of use, including emerging industrial opportunities. The original agreement was established in April 2014 for the development and commercialization of the PGX technology in select large markets like cosmeceuticals, functional food, nutraceuticals and pharmaceuticals. CZO.VN: 0.250 (unch)
Ceapro Raises an Additional $310,000 Through a Non-Brokered Private Placement
Marketwired - Wed Feb 04, 4:01PM CST
Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company"
, a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it has closed a $310,000 second tranche of its previously announced private placement of eight ( percent unsecured convertible debentures (the "Debentures" due December 31, 2016, with interest payable on June 30 and December 31 of each year. CZO.VN: 0.250 (unch)
